WHO ICTRP trial
bezafibrate for post operated bilirary atresia
JPRN-jRCTs031210066 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCTs031210066 |
|---|---|
| Public title | bezafibrate for post operated bilirary atresia |
| Scientific title | Prospective study of bezafibrate for post operated bilirary atresia |
| Primary sponsor | Terui Keita |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Conditions | Biliary Atresia Obstructive jaundice;D001656;Obstructive jaundice |
| Interventions | Bezafibrate 400 mg/day is orally administered to patients after biliary atresia in two divided doses after breakfast and dinner. |
| Registration date | Jun 5, 2021 |
| Target size | 10 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: